Vrije Universiteit Brussel, Center for Neurosciences, Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Brussels, Belgium.
IGF, Université de Montpellier, CNRS, Inserm, Montpellier, France.
Neuropsychopharmacology. 2022 Jun;47(7):1304-1314. doi: 10.1038/s41386-022-01324-2. Epub 2022 Apr 21.
Psychedelic-assisted psychotherapy gained considerable interest as a novel treatment strategy for fear-related mental disorders but the underlying mechanism remains poorly understood. The serotonin 2A (5-HT2A) receptor is a key target underlying the effects of psychedelics on emotional arousal but its role in fear processing remains controversial. Using the psychedelic 5-HT2A/5-HT2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) and 5-HT2A receptor knockout (KO) mice we investigated the effect of 5-HT2A receptor activation on emotional processing. We show that DOI administration did not impair performance in a spontaneous alternation task but reduced anxiety-like avoidance behavior in the elevated plus maze and elevated zero maze tasks. Moreover, we found that DOI did not block memory recall but diminished fear expression in a passive avoidance task. Likewise, DOI administration reduced fear expression in an auditory fear conditioning paradigm, while it did not affect retention of fear extinction when administered prior to extinction learning. The effect of DOI on fear expression was abolished in 5-HT2A receptor KO mice. Administration of DOI induced a significant increase of c-Fos expression in specific amygdalar nuclei. Moreover, local infusion of the 5-HT2A receptor antagonist M100907 into the amygdala reversed the effect of systemic administration of DOI on fear expression while local administration of DOI into the amygdala was sufficient to suppress fear expression. Our data demonstrate that activation of 5-HT2A receptors in the amygdala suppresses fear expression but provide no evidence for an effect on retention of fear extinction.
迷幻剂辅助心理治疗作为一种治疗恐惧相关精神障碍的新策略引起了相当大的关注,但其潜在机制仍知之甚少。血清素 2A(5-HT2A)受体是迷幻剂对情绪唤醒产生影响的关键靶点,但它在恐惧处理中的作用仍存在争议。使用迷幻剂 5-HT2A/5-HT2C 受体激动剂 2,5-二甲氧基-4-碘苯丙胺(DOI)和 5-HT2A 受体敲除(KO)小鼠,我们研究了 5-HT2A 受体激活对情绪处理的影响。我们发现,DOI 给药不会损害自发交替任务的表现,但会减少高架十字迷宫和高架零迷宫任务中的焦虑样回避行为。此外,我们发现 DOI 不会阻断记忆回忆,但会在被动回避任务中减轻恐惧表达。同样,DOI 给药减少了听觉恐惧条件反射范式中的恐惧表达,而在进行消退学习之前给药时,它不会影响恐惧消退的保留。在 5-HT2A 受体 KO 小鼠中,DOI 的作用被废除。DOI 给药会导致特定杏仁核核团中 c-Fos 表达的显著增加。此外,将 5-HT2A 受体拮抗剂 M100907 局部输注到杏仁核中可以逆转 DOI 对系统给药对恐惧表达的影响,而将 DOI 局部输注到杏仁核中足以抑制恐惧表达。我们的数据表明,杏仁核中 5-HT2A 受体的激活抑制了恐惧表达,但没有证据表明对恐惧消退的保留有影响。